By Counterforce Health Team in Cerezyme (imiglucerase) —

How to Get Cerezyme (Imiglucerase) Covered by Cigna in Illinois: Complete Coding, Appeals, and Prior Authorization Guide

Answer Box: To get Cerezyme (imiglucerase) covered by Cigna in Illinois, you need proper coding (ICD-10: E75.22, HCPCS: J1786), specialist documentation of Type 1 Gaucher disease with enzyme deficiency, and prior authorization through Cigna's specialty drug process. If denied, Illinois law gives you strong appeal rights including external review within 30 days. Start by having your specialist submit a PA request with complete lab results and clinical justification. Submit via Cigna provider portal or CoverMyMeds.

Table of Contents

Coding Basics: Medical vs. Pharmacy Benefit

Cerezyme (imiglucerase) for Type 1 Gaucher disease is always covered under the medical benefit, not pharmacy benefit. This is crucial for proper billing and prior authorization.

Why Medical Benefit?

  • Cerezyme requires IV infusion in a clinical setting
  • Billed using HCPCS J-codes, not NDC numbers alone
  • Administered by healthcare professionals, not self-administered
Tip: Never submit Cerezyme claims through pharmacy benefit channels. This will result in automatic denials and delays.

Coverage Path Summary:

  1. Specialist confirms Type 1 Gaucher disease diagnosis
  2. Prior authorization submitted to Cigna medical benefit team
  3. Claims processed under medical benefit using J1786 code
  4. Administered in infusion center or hospital outpatient setting

ICD-10 Mapping and Documentation

Primary ICD-10 Code: E75.22 (Gaucher disease type 1)

Required Documentation for E75.22

Your medical records must include:

Laboratory Evidence:

  • Enzyme activity testing showing deficient acid beta-glucosidase (GCase) activity in leukocytes or fibroblasts
  • Activity level <15% of normal controls
  • Genetic testing identifying pathogenic GBA1 gene variants (strongly recommended)

Clinical Symptoms:

  • Hepatosplenomegaly (enlarged liver/spleen)
  • Anemia and/or thrombocytopenia
  • Bone disease or bone pain
  • Growth delays (in pediatric patients)
Note: Dried blood spot (DBS) tests are initial screens only. Cigna requires confirmatory testing in leukocytes or fibroblasts for definitive diagnosis.

Documentation Language That Supports Coding:

  • "Confirmed Type 1 Gaucher disease with enzyme deficiency"
  • "GCase activity 8% of normal control" (specific numbers help)
  • "Pathogenic GBA1 mutations identified"
  • "Non-neuronopathic Gaucher disease"

Product Coding: HCPCS, J-Code, and NDC

Essential Coding Information

Code Type Value Description
HCPCS J-Code J1786 Injection, imiglucerase, 10 units
NDC Vial-specific 58468-0312-01 (400-unit vial)
ICD-10 E75.22 Gaucher disease type 1
Place of Service 11, 22, or 12 Office, hospital outpatient, or home

Units Calculation

Cerezyme Dosing:

  • Each vial contains 400 units
  • Common dosing: 2.5 units/kg three times weekly to 60 units/kg every two weeks
  • Billing units: Each J1786 represents 10 units of imiglucerase

Example Calculation:

  • Patient weight: 70 kg
  • Prescribed dose: 15 units/kg every two weeks
  • Total dose: 70 kg × 15 units/kg = 1,050 units
  • Billing: 1,050 ÷ 10 = 105 units of J1786
  • Vials needed: 1,050 ÷ 400 = 2.6 vials (round up to 3 vials)

NDC Requirements

Always include the 11-digit NDC on claims:

  • 58468-0312-01 (400-unit vial - most common)
  • Verify current NDC with your supplier before billing
  • Some payers require specific NDC formats
Important: Use JW modifier to report drug wastage when multiple vials are used but not fully administered.

Clean Request Anatomy

Prior Authorization Components

Patient Information:

  • Full name, DOB, Cigna member ID
  • Prescribing specialist information
  • ICD-10 code: E75.22

Clinical Justification:

  • Confirmed Type 1 Gaucher disease diagnosis
  • Enzyme test results with specific activity levels
  • Current symptoms and disease manifestations
  • Proposed dosing regimen with clinical rationale

Supporting Documentation:

  • Laboratory reports (enzyme and genetic testing)
  • Specialist consultation notes
  • Treatment history (if switching from another ERT)
  • Current imaging or lab results showing disease activity

Example PA Request Structure

Patient: [Name], DOB [Date], Member ID [Number]
Diagnosis: Type 1 Gaucher disease (ICD-10: E75.22)
Requested: Cerezyme (imiglucerase) 30 units/kg every 2 weeks

Clinical Summary:
- GCase enzyme activity: 6% of normal (attached lab report)
- Genetic testing: Compound heterozygote for GBA mutations
- Symptoms: Splenomegaly (18 cm), thrombocytopenia (platelet count 85,000)
- Weight: 65 kg
- Calculated dose: 1,950 units every 2 weeks

Prescriber: Dr. [Name], Hematologist
DEA: [Number], NPI: [Number]

Frequent Coding Pitfalls

Common Errors That Cause Denials

Unit Conversion Mistakes:

  • ❌ Billing per vial instead of per 10-unit increment
  • ❌ Miscalculating total units administered
  • ✅ Always divide total dose by 10 for J1786 billing units

Code Mismatches:

  • ❌ Using wrong ICD-10 code (E75.21 is Type 2, E75.23 is Type 3)
  • ❌ Billing under pharmacy benefit instead of medical
  • ✅ Verify E75.22 matches Type 1 diagnosis in notes

Documentation Gaps:

  • ❌ Missing enzyme test results
  • ❌ Incomplete dosing rationale
  • ✅ Include specific enzyme activity percentages

NDC Issues:

  • ❌ Using outdated NDC numbers
  • ❌ Omitting NDC entirely
  • ✅ Verify current NDC with manufacturer

Quick Fixes for Common Denials

Denial Reason Fix
"Diagnosis not supported" Submit enzyme test showing <15% activity
"Dosing outside guidelines" Provide clinical rationale for dose selection
"Missing specialist" Ensure prescriber is hematologist or specialist
"Units calculation error" Recalculate: total dose ÷ 10 = J1786 units

Verification Steps

Pre-Submission Checklist

Code Verification:

  1. Confirm current HCPCS codes at CMS HCPCS lookup
  2. Verify NDC with manufacturer at Cerezyme.com
  3. Cross-check ICD-10 code with diagnosis documentation

Cigna-Specific Requirements:

  1. Check current Cigna specialty drug policies for updates
  2. Verify prior authorization form requirements
  3. Confirm preferred submission method (CoverMyMeds vs. fax)

Documentation Review:

  1. Ensure all lab results are attached
  2. Verify specialist credentials are current
  3. Confirm dosing calculations match prescription
Pro Tip: Call Cigna provider services at the number on your provider card to verify current PA requirements before submitting.

Quick Audit Checklist

Pre-Submission Review

☐ Patient Information

  • Cigna member ID verified
  • Correct patient demographics
  • Active coverage confirmed

☐ Clinical Documentation

  • Type 1 Gaucher disease confirmed with E75.22
  • Enzyme test results <15% normal activity
  • Genetic testing results (if available)
  • Specialist consultation notes

☐ Coding Accuracy

  • J1786 units calculated correctly
  • NDC matches vial size used
  • ICD-10 code E75.22 documented
  • Place of service code appropriate

☐ Prior Authorization

  • PA form completed by specialist
  • All required attachments included
  • Submission method confirmed
  • Expected timeline noted

☐ Billing Preparation

  • Units calculation double-checked
  • Waste documentation prepared (if applicable)
  • Claim routing to medical benefit confirmed

Appeals Process in Illinois

Illinois provides strong patient protection for insurance appeals, with specific timelines and external review rights.

Internal Appeals Timeline

Standard Appeals:

  • Deadline: 180 days from denial date
  • Decision timeframe: 15 business days for pre-service
  • Required: Written request with clinical justification

Expedited Appeals:

  • When to use: Delay would jeopardize health
  • Decision timeframe: 24 hours
  • Documentation: Physician attestation of urgency

External Review Process

Illinois law guarantees independent external review after internal appeals are exhausted.

Key Requirements:

  • Deadline: 30 days from final internal denial (shorter than many states)
  • Cost: Free to patients (insurer pays)
  • Reviewer: Board-certified physician with Gaucher disease expertise
  • Decision timeframe: 5 business days after materials received

How to Request External Review:

  1. Contact Illinois Department of Insurance at 877-527-9431
  2. Complete external review application
  3. Submit within 30 days of final denial
  4. Include all medical records and denial letters
Illinois-Specific Advantage: The state's Health Carrier External Review Act provides binding decisions that insurers must honor.

When to Escalate Further

Illinois Attorney General Health Care Bureau:

  • Phone: 877-305-5145
  • Can intervene informally with insurers
  • Helpful for complex rare disease cases

Counterforce Health specializes in turning insurance denials into targeted, evidence-backed appeals. Their platform analyzes denial letters and plan policies to identify specific denial reasons and draft point-by-point rebuttals aligned with payer requirements. For complex cases like Cerezyme coverage, they can help gather the right clinical evidence and regulatory citations. Visit counterforcehealth.org to learn more about their appeal assistance services.

FAQ

Q: How long does Cigna prior authorization take for Cerezyme in Illinois? A: Standard PA decisions are made within 72 hours of receiving complete documentation. Expedited reviews (for urgent cases) are decided within 24 hours.

Q: What if Cerezyme is non-formulary on my Cigna plan? A: You can request a formulary exception with clinical justification. Your specialist must document why preferred alternatives are inappropriate or ineffective.

Q: Can I request expedited appeal if my infusion is delayed? A: Yes. If delaying Cerezyme would jeopardize your health, request expedited review. Your physician must provide written attestation of medical urgency.

Q: Does step therapy apply if I've failed other ERTs outside Illinois? A: Prior therapy failures documented in your medical record should support step therapy override, regardless of where treatment occurred. Ensure your specialist includes this history in the PA request.

Q: What happens if my external review is approved? A: External review decisions are binding in Illinois. Cigna must provide coverage as determined by the independent physician reviewer.

Q: How do I find a Gaucher disease specialist in Illinois? A: Contact the National Gaucher Foundation for specialist referrals, or ask your current physician for a referral to a hematologist experienced with lysosomal storage disorders.

From our advocates: "We've seen Cerezyme appeals succeed when families gathered comprehensive enzyme testing results and had their specialist clearly document why the prescribed dose was medically necessary. The key is showing Cigna exactly how the patient meets their published criteria - don't assume they'll connect the dots themselves."

When working with Counterforce Health, patients and clinicians get access to payer-specific templates and evidence libraries that can significantly improve approval rates for complex specialty drugs like Cerezyme.

Sources & Further Reading

Disclaimer: This information is for educational purposes only and does not constitute medical or legal advice. Insurance coverage requirements change frequently. Always verify current requirements with Cigna and consult your healthcare provider for medical decisions. For assistance with appeals, contact the Illinois Department of Insurance at 877-527-9431.

Powered by Counterforce Health—AI that turns drug denials into evidence-based appeals patients and clinicians can submit today.